Protagonist Therapeutics Inc. (PTGX): Advancing Treatments for Autoimmune Diseases
State Street Corp's Strategic Acquisition in Protagonist Therapeutics Inc
TD Cowen Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $65
Capitulation in Biotech Is Near, as Well as a Rally – Piper Sandler
Truist Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating
Truist Financial Issues a Buy Rating on Protagonist Therapeutics (PTGX)
TD Cowen Initiates Protagonist Therapeutics(PTGX.US) With Buy Rating, Announces Target Price $65
TD Cowen analyst Tara Bancroft initiates coverage on $Protagonist Therapeutics(PTGX.US)$ with a buy rating, and sets the target price at $65.According to TipRanks data, the analyst has a success
Express News | Protagonist Therapeutics Inc : TD Cowen Initiates Coverage With Buy Rating; Target Price $65
The 8.6% Return This Week Takes Protagonist Therapeutics' (NASDAQ:PTGX) Shareholders Five-year Gains to 231%
H.C. Wainwright Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $50
H.C. Wainwright analyst Douglas Tsao maintains $Protagonist Therapeutics(PTGX.US)$ with a buy rating, and adjusts the target price from $40 to $50.According to TipRanks data, the analyst has a
Analysts Offer Insights on Healthcare Companies: Walgreens Boots Alliance (WBA), Belite Bio, Inc. ADR (BLTE) and Protagonist Therapeutics (PTGX)
Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines
Truist Financial Initiates Protagonist Therapeutics(PTGX.US) With Buy Rating, Announces Target Price $60
Truist Financial analyst Srikripa Devarakonda initiates coverage on $Protagonist Therapeutics(PTGX.US)$ with a buy rating, and sets the target price at $60.According to TipRanks data, the analyst
Truist Initiates Protagonist Therapeutics at Buy With $60 Price Target
Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
Protagonist Therapeutics Price Target Cut to $43.00/Share From $45.00 by JMP Securities
Protagonist Therapeutics Is Maintained at Market Outperform by JMP Securities
HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $40
Protagonist Therapeutics Analyst Ratings
Express News | Protagonist Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $40 From $38